After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...